• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by iTeos Therapeutics Inc.

    9/30/24 9:00:13 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ITOS alert in real time by email
    SC 13G 1 o927246sc13g.htm

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

     

    SCHEDULE 13G

     

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    iTeos Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

     

     

    46565G104

    (CUSIP Number)

     

     

     

     

    September 26, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨       Rule 13d-1(b)

     

    x       Rule 13d-1(c)

     

    ¨       Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 10 pages 
     

     

    CUSIP No.  46565G104

     

    13G Page 2 of 10 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC

     

    2 Check the Appropriate Box if a Member of a Group*

    (a) o

    (b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY

    Owned by

    6

    Shared Voting Power

     

    2,407,800

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    2,407,800

     

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    2,407,800

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    6.6%

     

    12

    type of reporting person

     

    OO

     

     

     Page 2 of 10 pages 
     

     

    CUSIP No. 46565G104

     

    13G Page 3 of 10 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Kevin Tang

     

    2 Check the Appropriate Box if a Member of a Group*

    (a) o

    (b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    united states

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY

    Owned by

    6

    Shared Voting Power

     

    2,407,800

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    2,407,800

     

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    2,407,800

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    6.6%

     

    12

    type of reporting person

     

    IN

     

     

     Page 3 of 10 pages 
     

     

    CUSIP No. 46565G104

     

    13G Page 4 of 10 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP

     

    2 Check the Appropriate Box if a Member of a Group*

    (a) o

    (b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY

    Owned by

    6

    Shared Voting Power

     

    2,307,800

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    2,307,800

     

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    2,307,800

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    6.3%

     

    12

    type of reporting person

     

    pN

     

     

     Page 4 of 10 pages 
     

     

    CUSIP No. 46565G104

     

    13G Page 5 of 10 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS III, INC

     

    2 Check the Appropriate Box if a Member of a Group*

    (a) o

    (b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    NEVADA

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY

    Owned by

    6

    Shared Voting Power

     

    100,000

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    100,000

     

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    100,000

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0.3%

     

    12

    type of reporting person

     

    CO

     

     

     Page 5 of 10 pages 
     

     

    CUSIP No. 46565G104

     

    13G Page 6 of 10 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS IV, INC

     

    2 Check the Appropriate Box if a Member of a Group*

    (a) o

    (b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    NEVADA

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    0

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    0

     

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0%

     

    12

    type of reporting person

     

    CO

     

     

     Page 6 of 10 pages 
     

     

    Item 1(a).Name of Issuer:

     

    iTeos Therapeutics, Inc., a Delaware corporation (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    321 Arsenal Street, Watertown, MA 02472

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Management, LLC, the general partner of Tang Capital Partners, LP (“Tang Capital Management”); Kevin Tang, the manager of Tang Capital Management and Chief Executive Officer of Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc.; Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Partners III, Inc. (“Tang Capital Partners III”); and Tang Capital Partners IV, Inc. (“Tang Capital Partners IV”).

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    The address of Tang Capital Management, Kevin Tang and Tang Capital Partners is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of Tang Capital Partners III and Tang Capital Partners IV is 5955 Edmond Street, Las Vegas, NV 89118.

     

    Item 2(c).Citizenship:

     

    Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen. Tang Capital Partners is a Delaware limited partnership. Tang Capital Partners III and Tang Capital Partners IV are Nevada corporations that are indirectly wholly owned by Tang Capital Partners.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.001 per share (the “Common Stock”)

     

    Item 2(e).CUSIP Number 46565G104

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    Tang Capital Management. Tang Capital Management beneficially owns 2,407,800 of the Issuer’s Common Stock.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners, Tang Capital Partners III and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 2,407,800 of the Issuer’s Common Stock.

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners, Tang Capital Partners III and Tang Capital Management.

     

     Page 7 of 10 pages 
     

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 2,307,800 of the Issuer’s Common Stock.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Partners III. Tang Capital Partners III beneficially owns 100,000 of the Issuer’s Common Stock.

     

    Tang Capital Partners III shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    The percentages used herein are based on 36,521,845 shares of Common Stock outstanding as of August 1, 2024, as set forth in the Issuer’s Quarterly Report filed on Form 10-Q that was filed with the Securities and Exchange Commission on August 8, 2024.

     

    (b)Percent of Class:

     

    Tang Capital Management 6.6%
    Kevin Tang 6.6%
    Tang Capital Partners 6.3%
    Tang Capital Partners III 0.3%
    Tang Capital Partners IV 0.0%

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote:

     

    Tang Capital Management 0 shares
    Kevin Tang 0 shares
    Tang Capital Partners 0 shares
    Tang Capital Partners III 0 shares
    Tang Capital Partners IV 0 shares

     

    (ii)shared power to vote or to direct the vote:

     

    Tang Capital Management 2,407,800 shares
    Kevin Tang 2,407,800 shares
    Tang Capital Partners 2,307,800 shares
    Tang Capital Partners III 100,000 shares
    Tang Capital Partners IV 0 shares

     

    (iii)sole power to dispose or to direct the disposition of:

     

    Tang Capital Management 0 shares
    Kevin Tang 0 shares
    Tang Capital Partners 0 shares
    Tang Capital Partners III 0 shares
    Tang Capital Partners IV 0 shares

     

    (iv)shared power to dispose or to direct the disposition of:

     

    Tang Capital Management 2,407,800 shares
    Kevin Tang 2,407,800 shares
    Tang Capital Partners 2,307,800 shares
    Tang Capital Partners III 100,000 shares
    Tang Capital Partners IV 0 shares

     

     Page 8 of 10 pages 
     

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 9 of 10 pages 
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: September 30, 2024  

     

     

    TANG CAPITAL PARTNERS, LP

     

    By: Tang Capital Management, LLC, its General Partner

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

    TANG CAPITAL PARTNERS III, INC

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Chief Executive Officer  

     

    TANG CAPITAL PARTNERS IV, INC

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Chief Executive Officer  

     

    TANG CAPITAL MANAGEMENT, LLC

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 10 of 10 pages

     

     

     

    Get the next $ITOS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ITOS

    DatePrice TargetRatingAnalyst
    5/14/2025$9.00Outperform → Market Perform
    Leerink Partners
    5/14/2025Buy → Neutral
    H.C. Wainwright
    5/13/2025Overweight → Neutral
    Analyst
    8/13/2024$31.00Overweight
    Wells Fargo
    12/13/2021$37.00 → $54.00Buy
    HC Wainwright & Co.
    11/12/2021$55.00 → $54.00Outperform
    SVB Leerink
    8/13/2021$56.00 → $55.00Outperform
    SVB Leerink
    More analyst ratings

    $ITOS
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by iTeos Therapeutics Inc.

      SCHEDULE 13D/A - iTeos Therapeutics, Inc. (0001808865) (Subject)

      5/15/25 5:30:55 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by iTeos Therapeutics Inc.

      SCHEDULE 13G/A - iTeos Therapeutics, Inc. (0001808865) (Subject)

      5/15/25 4:35:39 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by iTeos Therapeutics Inc.

      SCHEDULE 13G - iTeos Therapeutics, Inc. (0001808865) (Subject)

      5/15/25 4:15:23 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ITOS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

      – GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data, iTeos and GSK have agreed to terminate the belrestotug development program – iTeos has initiated a targeted review of strategic alternatives to maximize shareholder value WATERTOWN, Mass. and GOSSELIES, Belgium, May 13, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported topline results from an updated interim analysis of GALAXIES Lung-201, the Phase 2 platform s

      5/13/25 7:55:00 AM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates

      - Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Cash balance and investment balance of $624.3 million as of March 31, 2025 expected to provide runway through 2027 WATERTOWN, Mass. and GOSSELIES, Belgium, April 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the first quarter ended March 31, 2025 and provided a business update. "The seco

      4/28/25 4:30:00 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025

      WATERTOWN, Mass. and GOSSELIES, Belgium, March 25, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the poster presentations of preclinical data on EOS-215, a potential best-in-class antibody targeting TREM2, and a novel small molecule inhibiting PTPN1/2 at the American Association for Cancer Research (AACR) Annual Meeting, being held April 25-30, 2025 in Chicago, Illinois. Poster Presentation Details Abstract 3136, "EOS-215, a first-in-class TREM2 antagonist, designed to reprogram the tumor microenvironment

      3/25/25 4:35:00 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ITOS
    Leadership Updates

    Live Leadership Updates

    See more
    • iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer

      WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 (GLOBE NEWSWIRE) --  iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of David Feltquate, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Feltquate will be responsible for overseeing the Company's clinical development and regulatory strategies. "As iTeos reaches a pivotal moment towards recognizing our ambition to become a leading oncology company, we're excited to welcome Dr. Feltquate as Chief Medical Officer," said Michel Detheux, Ph.D., presi

      8/5/24 7:00:00 AM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors

      WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of Jill DeSimone to its Board of Directors, effective March 7, 2024, where she will serve on the Company's audit committee. "Expanding our board with industry leaders and oncology veterans with commercial, scientific, and corporate portfolio strategy experience is of the utmost importance for iTeos. After the recent appointment of Servier's David Lee, we are thrilled to welcome Jill DeSimone to o

      3/6/24 7:01:00 AM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

      - Multiple clinical milestones across portfolio anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC- Completed enrollment of third dose cohort in Phase 1 trial of EOS-984- Preclinical presentations on role of ENT1 at SITC Spring Scientific and profile of EOS-984 at AACR annual meeting- Cash and investment balance of $632.7 million as of December 31, 2023 expected to provide runway through 2026 across a number of impactful portfolio milestones- Oncology veterans Jill DeSimone and David K. Lee to join Board of Directors WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NA

      3/6/24 7:00:00 AM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ITOS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Gall Matthew bought $38,635 worth of shares (5,000 units at $7.73), increasing direct ownership by 8% to 65,429 units (SEC Form 4)

      4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

      11/19/24 7:59:14 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gall Matthew bought $41,850 worth of shares (5,000 units at $8.37), increasing direct ownership by 35% to 19,429 units (SEC Form 4)

      4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

      10/12/23 5:09:33 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ITOS
    Financials

    Live finance-specific insights

    See more
    • iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

      - Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose- >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy- Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations- GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting- iTeos to host a conference call on Monday, September 16, 2024 at 8:00am ET WATERTOWN, Mass. and GOSSELIES, Belgium, Sept. 14, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stag

      9/14/24 2:30:00 AM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • iTeos Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

      - First patients dosed in clinical trial of anti-TIGIT monoclonal antibody, EOS-448, in combination with pembrolizumab and with inupadenant in patients with solid tumors - Advanced clinical development of inupadenant, EOS-850, an A2A receptor antagonist, with initiation of an expansion in PD-1 resistant melanoma in combination with pembrolizumab as well as a planned study further exploring novel predictive biomarkers - Received full upfront payment of $625MM at closing of development and commercialization collaboration agreement with GSK for EOS-448 - Cash balance of $899.8MM as of September 30, 2021, providing runway into 2026 to support clinical development plans for EOS-448 and inupad

      11/10/21 4:01:00 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • iTeos to Report Third Quarter 2021 Financial Results on November 10, 2021

      CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, November 10, 2021 to report its third quarter 2021 financial results and provide a corporate update. To access the live conference call, please dial 833-927-1758 (domestic) or 929-526-1599 (international) and refer to conference access code 861337. A live audio webcast of the event will also be accessible from

      11/3/21 7:00:00 AM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ITOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • iTeos Therapeutics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded iTeos Therapeutics from Outperform to Market Perform and set a new price target of $9.00

      5/14/25 8:56:56 AM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • iTeos Therapeutics downgraded by H.C. Wainwright

      H.C. Wainwright downgraded iTeos Therapeutics from Buy to Neutral

      5/14/25 8:56:56 AM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • iTeos Therapeutics downgraded by Analyst

      Analyst downgraded iTeos Therapeutics from Overweight to Neutral

      5/13/25 1:50:45 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ITOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Former 10% Owner Gadicke Ansbert sold $8,317,364 worth of shares (1,031,931 units at $8.06) (SEC Form 4)

      4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

      5/15/25 5:34:15 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Former 10% Owner Mpm Bioventures 2018, L.P. sold $5,079,339 worth of shares (630,191 units at $8.06) (SEC Form 4)

      4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

      5/15/25 5:33:28 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Former 10% Owner Mpm Bioventures 2014, L.P. sold $5,079,339 worth of shares (630,191 units at $8.06) (SEC Form 4)

      4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

      5/15/25 5:32:22 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ITOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by iTeos Therapeutics Inc.

      SC 13G - iTeos Therapeutics, Inc. (0001808865) (Subject)

      11/21/24 8:27:38 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by iTeos Therapeutics Inc.

      SC 13D/A - iTeos Therapeutics, Inc. (0001808865) (Subject)

      11/19/24 9:57:32 AM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by iTeos Therapeutics Inc.

      SC 13D/A - iTeos Therapeutics, Inc. (0001808865) (Subject)

      11/18/24 9:57:13 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care